Ritholtz Wealth Management Has $83,000 Stock Position in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Ritholtz Wealth Management reduced its position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 65.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,479 shares of the company’s stock after selling 33,782 shares during the period. Ritholtz Wealth Management owned approximately 0.11% of Sensus Healthcare worth $83,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SRTS. JPMorgan Chase & Co. acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $27,000. Barclays PLC acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $35,000. BNP Paribas Financial Markets acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $47,000. Wealth Enhancement Advisory Services LLC acquired a new position in Sensus Healthcare during the first quarter valued at approximately $71,000. Finally, IFP Advisors Inc acquired a new position in Sensus Healthcare during the fourth quarter valued at approximately $95,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on SRTS shares. Maxim Group lowered their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Lake Street Capital lowered their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Wall Street Zen downgraded shares of Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Sunday. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Sensus Healthcare in a report on Friday, April 4th. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

Sensus Healthcare Stock Performance

Shares of NASDAQ:SRTS opened at $4.73 on Friday. The company has a fifty day moving average of $4.68 and a 200-day moving average of $5.61. The company has a market capitalization of $77.76 million, a PE ratio of 47.30 and a beta of 1.32. Sensus Healthcare, Inc. has a 52-week low of $4.01 and a 52-week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). The company had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.23 million. Sensus Healthcare had a return on equity of 3.34% and a net margin of 4.56%. On average, equities analysts forecast that Sensus Healthcare, Inc. will post 0.32 EPS for the current fiscal year.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.